Roivant Sciences Ltd. (ROIV) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Positive Phase 2 brepocitinib data announced 2026‑02‑06 and a same‑day business update call have already sparked a ~23% 21‑day rally and 52‑week highs; continued analyst reaction and follow‑on clinical/regulatory detail create near‑term upside for event‑driven traders despite ongoing cash burn and litigation risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • High Cash Burn • Weak Revenue ROIV has an exceptionally strong balance sheet with $4.7B in cash and investments versus just $107.4M of debt and an 18.4x current ratio, but persistent losses, heavy cash burn, and minimal revenue keep earnings quality weak and the valuation stretched.
Price Behavior
Key Price Behavior Insights: • Choppy rebound • Support holding • Failed breakout Support Level: $28.25-$28.58 Resistance Level: $29.50-$30.00 Over the last month, ROIV is modestly higher but choppy, with $28.25-$28.58 acting as support and $29.50-$30.00 capping the near term after a failed breakout above $32.41.
Sentiment & News
Key News Insights: • Conference cadence • Pipeline catalysts • Cash strength Roivant's recent conference presentations and pipeline updates offset a softer-than-expected fiscal Q4, keeping investor focus on clinical catalysts like IMVT-1402, mosliciguat, and brepocitinib amid a strong $4.3 billion cash position.
AI Summary
ROIV now looks less like a broad biotech optionality play and more like a late-stage, catalyst-driven monetization story: its $4.7B cash pile de-risks funding, but the stock's upside now depends on brepocitinib and a few other lead assets converting strong clinical data into approvals, launches, and real revenue before ongoing cash burn erodes that cushion.
Description
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops therapeutics across oncology, hematology, immunology, dermatology and infectious disease. It advances a pipeline of clinical and preclinical candidates addressing conditions from solid tumors and sickle cell disease to metabolic bone disorders and a range of autoimmune and dermatologic illnesses. The company was founded in 2014 and is headquartered in London, United Kingdom.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 11 | Feb 18 | ROIV | Roivant Sciences Ltd. | Positive Phase 2 brepocitinib data announced 2026‑02‑06 and a same‑day business update call have already sparked a ~23% 21‑day rally and 52‑week highs; continued analyst reaction and follow‑on clinical/regulatory detail create near‑term upside for event‑driven traders despite ongoing cash burn and litigation risk. | Closed | +2.5% |